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Background. Oral combination therapy with fluoroquinolones plus rifampicin is a promising alternative to
standard parenteral therapy for staphylococcal infections.
Methods. In a multicenter, randomized trial, we compared the efficacy, safety, and length of hospital stay for
patients with staphylococcal infections treated either with an oral combination of a fluoroquinolone (fleroxacin)
plus rifampicin or with standard parenteral treatment (flucloxacillin or vancomycin). Patients were included if
cultures showed the presence of bacteremia or deep-seated infections with Staphylococcus aureus (104 patients) or
catheter-related bacteremia due to drug-susceptible, coagulase-negative staphylococci (23 patients).
Results. The cure rate in the intention-to-treat analysis was 78% for the fleroxacin-rifampicin group (68
patients) and 75% for the standard therapy group (59 patients; 47 received flucloxacillin, and 12 received van-
comycin); in the population of clinically evaluable patients ( ), the cure rate was 82% and 80%, respectively;np 119
and in the population of microbiologically evaluable patients ( ), the cure rate was 86% and 84%, re-np 103
spectively. Clinical and bacteriological failures after S. aureus infections were documented in similar proportions
of patients. The median length of hospital stay after study entry was 12 days in the fleroxacin-rifampicin group,
compared with 23 days in the standard treatment group ( ). More adverse events probably related to thePp .006
study drug were reported in the fleroxacin-rifampicin group than in the standard therapy group (15 of 68 vs. 5
of 59 patients; ).Pp .05
Conclusions. This study suggests that an oral regimen containing a fluoroquinolone plus rifampicin may be
effective for treating staphylococcal infections, allowing earlier discharge from the hospital.
Staphylococcal infections are common and represent
an important therapeutic problem, because bacterial
complications frequently arise [1]. Therefore, such in-
fections require adequate management and highly ef-
fective anti-infective treatment [2]. The treatment
currently recommended is a prolonged course of a par-
enteral, semisynthetic penicillin or vancomycin. How-
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ever, this treatment entails a risk of complications and
increased costs because of prolonged hospital stay and
adverse events associated with the use of intravenous
catheters.
Previous studies have demonstrated the efficacy of
oral antibiotic treatment with rifampicin and cipro-
floxacin in the treatment of staphylococcal infections
of implanted foreign bodies [3] and of right-sided en-
docarditis in injection drug abusers [4, 5]. Although it
has become common practice to use oral treatment
combinations of fluoroquinolones with rifampicin for
staphylococcal infections, only a few randomized trials
have assessed the efficacy of this treatment regimen for
other patient populations [6].
Experimental studies have shown that newer fluor-
oquinolones have equivalent or even better anti-staph-
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ylococcal efficacy when given in combination with rifampicin,
compared with fluoroquinolone monotherapy [7]. The phar-
macokinetics of oral fleroxacin is particularly well understood,
with regard both to the bioavailability in bacteremic subjects
(reaching almost 100%) and the interaction with rifampicin in
healthy volunteers [8, 9]. In addition, its long half-life (10 h)
allows once-daily oral administration [10]. Fleroxacin is elim-
inated primarily by renal clearance, with ∼60%–70% of a dose
being recovered unchanged in the urine within 96 h [11]. This
randomized trial compared the efficacy, safety, and length of
hospital stay for patients with staphylococcal infections treated
either with oral fleroxacin-rifampicin or with standard par-
enteral therapy (flucloxacillin or vancomycin).
METHODS
Study design. This was a prospective, randomized, open-label,
multicenter trial comparing mainly oral fleroxacin-rifampicin
with parenteral flucloxacillin for the treatment of staphylococcal
infections. Patients randomized to receive flucloxacillin who were
allergic to penicillin, or in whom the infection was due to meth-
icillin-resistant Staphylococcus aureus (MRSA) or to methicillin-
resistant coagulase-negative staphylococci (CoNS) susceptible to
fleroxacin and rifampicin, received intravenous vancomycin as
alternative therapy. Patients were stratified prospectively into 2
study arms, according to the presence or absence of catheter-
related staphylococcal bacteremia.
In each center, consecutive patients who fulfilled the inclu-
sion criteria were randomly assigned by sealed, numbered en-
velopes to 1 of the 2 treatment groups. Each study center had
its own block numbers for randomization so that numbers were
allocated sequentially in the order in which the patients were
enrolled.
The trial included 5 tertiary care centers in Switzerland (Ge-
neva, Basel, Lausanne, Fribourg, and Bern) and 1 hospital in
Brussels, Belgium. The investigators obtained approval for the
study by the human research ethics committee at each partic-
ipating center.
Study population. Adult patients (age,18 years old) with
staphylococcal infections were eligible for this study provided
that they had given informed consent and that pure bacteri-
ologic cultures showed the presence of bacteremia and/or deep-
seated infection with S. aureus or the presence of catheter-
related bacteremia due to CoNS that was susceptible to
fleroxacin, rifampicin, and flucloxacillin (or to vancomycin, in
the case of methicillin resistance or allergy). At study entry,
patients were to have at least 1 of the following types of staph-
ylococcal infection requiring anti-infective treatment: lower res-
piratory tract infection (e.g., pneumonia), infection of a serous
membrane (e.g., empyema), acute bone and joint infection
(e.g., osteomyelitis and/or arthritis), chronic bone infection
(provided that surgical debridement was done and that any
foreign material was removed), complicated urinary tract in-
fection (e.g., prostatitis), other deep-seated abscess, right-sided
endocarditis, or catheter-related bacteremia. Catheter-related
bacteremia had to fulfill 1 of the following criteria: pus at the
insertion site and isolation of the same organism from pus and
the bloodstream; a positive result of a semiquantitative or quan-
titative culture of the distal tip with concomitant isolation of
S. aureus or CoNS from the bloodstream; or differential quan-
titative cultures of blood, with a 10-fold colony count of
organisms concomitantly isolated from blood drawn through
a central venous catheter and from cultures of peripheral blood
specimens.
Exclusion criteria. Chronic bone infections without sur-
gical debridement were excluded, as were nonbacteremic in-
fections of the skin, because the latter vary in severity and
therefore involve an excessively heterogeneous patient popu-
lation [12]. Infections associated with foreign bodies that were
kept in place were included in another study [3]. Left-sided
endocarditis was excluded because of a high excess mortality,
ruling out an early switch to oral treatment [13].
Pregnant and lactating women were excluded, as was any
subject with hypersensitivity or staphylococci resistant to fluor-
oquinolones or rifampicin. Other exclusion criteria included
any of the following: refusal to substitute oral contraception
for another form during treatment (for women), significant
impairment of hepatic function, concomitant infections at
other sites requiring broad-spectrum antibiotics, and treatment
with other antimicrobials for 172 h.
Study treatment. Hospitalized patients were randomized
to receive either oral fleroxacin-rifampicin or standard par-
enteral treatment (flucloxacillin or vancomycin). Patients ran-
domized to receive fleroxacin (400 mg q.d.) plus rifampicin
(600 mg q.d.) received medication once daily; initially this could
be administered intravenously for 24 h, but parenteral therapy
was to be switched to the oral route as soon as possible. Flu-
cloxacillin (2 g q.i.d.) and vancomycin (1 g b.i.d.; adapted to
serum levels if necessary) were administered only by the in-
travenous route. Before study inclusion, patients in both treat-
ment groups who required empirical coverage for gram-positive
organisms until receipt of definitive results of susceptibility tests
were allowed to receive antistaphylococcal agents for up to 72
h after the onset of infection. The recommended duration of
anti-infective treatment was as follows: for bacteremia associ-
ated with skin-related infections or catheter-related bacteremia,
14 days; for bacteremia associated with deep-seated infections,
28 days; and for bacteremia with vertebral osteomyelitis, 42
days.
Evaluation and monitoring. Assessment of results of bac-
teriological analysis, clinical signs and symptoms of disease, and
safety were made at baseline, during therapy (day 7 after the
initiation of treatment), at the end of treatment, and 3 months
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(1 week) after the end of treatment. In cases of bacteremia,
endocarditis and secondary septic foci had to be excluded by
means of additional diagnostic testing during follow-up. In the
event of a complicated clinical course (e.g., sustained bacter-
emia), complementary investigations with imaging tests were
strongly recommended.
Antimicrobial susceptibility testing was done in accordance
with NCCLS guidelines by use of disk diffusion techniques.
Fleroxacin MICs were interpreted as follows: susceptible, 2
mg/mL; and resistant, 8 mg/mL.
All included patients were monitored for signs of drug tox-
icity and adverse events. Toxicity was reported to be probably
related to antibiotics if it began when drugs were first admin-
istered, abated after discontinuation of drug use, and was not
clearly attributable to other causes.
Analysis of efficacy. Three different patient populations
were analyzed: the intention-to-treat (ITT) patient population,
the clinically evaluable patient population, and the microbio-
logically evaluable patient population. The ITT population in-
cluded all patients who received study medication for at least
24 h. Patients were considered to be clinically evaluable if they
met the inclusion criteria and did not satisfy any exclusion
criteria, received study drugs for at least 5 days, and did not
receive effective antistaphylococcal therapy for 172 h prior to
study inclusion. Patients were not clinically evaluable for rea-
sons such as improper duration of therapy not related to ad-
verse events or treatment failure, concomitant receipt of an-
tistaphylococcal therapy after randomization, or inability to
meet all predefined entry criteria. Microbiologically evaluable
patients included all clinically evaluable patients who had un-
dergone 3 months of follow-up with evaluation of bacterial
eradication or relapse.
Primary efficacy variables were the clinical and microbio-
logical outcomes, which were based on resolution of infection
at the end of the follow-up period. Criteria for assessing clinical
outcome were as follows: cure was defined as clinical signs and
symptoms present at baseline that had resolved by the final
clinical assessment, and failure was defined as no improvement
or deterioration of the clinical condition that required change
from the randomized treatment regimen. Bacteriologic cure was
defined as eradication of the initially susceptible pathogen. Bac-
teriologic failure was defined as microbiologically documented
persistence or relapse of the original pathogen. Secondary out-
come variables evaluated were mortality and length of hospital
stay after randomization.
Statistical analysis. A sample size of at least 130 evaluable
patients per treatment group was initially required to show the
equivalence of the treatments. The calculation was based on a
clinical response rate of 70% under standard treatment, a D of
30%, a power of 80%, and a predetermined level of significance
of .05 (2-sided test). An intermediate analysis done after 35
patients completed the study revealed higher response rates
than were initially hypothesized. For this reason, and because
of slow patient recruitment, the final analysis was done on the
2 pooled study arms with at least 50 patients per treatment
group.
Categorical variables were compared by the x2 test or Fisher’s
exact test. For continuous variables, we used Student’s t test
or a nonparametric test when appropriate. Relative risks and
95% CIs were calculated for the difference in proportions be-
tween the 2 treatment groups.
RESULTS
Study population. Of the 130 patients enrolled, 69 were
randomized to receive fleroxacin-rifampicin, and 61 were ran-
domized to receive flucloxacillin or vancomycin. All patients
(except 3) who received study medication for !24 h were in-
cluded in the ITT analysis. In the ITT population, 68 patients
were assigned to receive fleroxacin-rifampicin, 47 received flu-
cloxacillin, and 12 received vancomycin (7 patients had a pen-
icillin allergy, 4 had methicillin-resistant CoNS, and 1 had
MRSA). The study groups and reasons for nonevaluability are
shown in figure 1. Baseline clinical and demographic charac-
teristics of the ITT population were similar for both treatment
groups (table 1).
Infection sites and microbiology. The proportional fre-
quency of infection-related diagnoses and causative microor-
ganisms was similar in the 2 groups (table 1). Leading sources
of infection were catheter-related bacteremia (in 55 patients)
and acute bone and joint infection (in 35 patients). Secondary
bacteremia unrelated to catheters was present in 40 patients.
Eight patients (12%) in the fleroxacin-rifampicin group and 7
patients (12%) in the standard treatment group had signs of
severe sepsis with 2 organ dysfunctions ( ). OrganismsPp .9
identified were S. aureus (in 104 patients) and CoNS (in 23
patients) in cases of catheter-related bacteremia. In each study
arm, 1 case of MRSA infection and 4 cases of methicillin-
resistant CoNS infection were included.
Antibiotic treatment. In the ITT patient population, the
mean duration (SD) of antibiotic treatment was days21 16
in the fleroxacin-rifampicin group and days in the19 11
standard parenteral treatment group ( ). The switch toPp .41
the oral regimen in the fleroxacin-rifampicin group was done
after a median of 1 day of intravenous therapy (interquartile
range, 1–3 days). In both treatment groups, the same propor-
tion of patients (93%) received empirical antistaphylococcal
therapy for up to 72 h before study inclusion. The most com-
monly administered antistaphylococcal agents before random-
ization were amoxicillin–clavulanic acid (to 40 patients), flu-
cloxacillin (to 30), and vancomycin (to 20).
The proportions of patients who discontinued therapy pre-
maturely were similar between treatment groups. Overall, 15
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Figure 1. Trial profile and flow diagram of patient enrollment status in each stage of the study, including reasons for nonevaluability
patients (22%) in the fleroxacin-rifampicin group and 14 (24%)
in the standard parenteral treatment group discontinued the
assigned study medication ( ). Reasons for discontin-Pp .78
uation of study treatment were drug toxicity ( ; 6 patientsnp 10
in the fleroxacin-rifampicin group and 4 in the standard treat-
ment group), lack of efficacy ( ; 4 in the fleroxacin-rifam-np 6
picin group and 2 in the standard treatment group), protocol
violation ( ; 3 in the fleroxacin-rifampicin group and 5np 8
in the standard treatment group) or death ( ; 2 in thenp 5
fleroxacin-rifampicin group and 3 in the standard treatment
group).
Efficacy. Analysis of response rates in the ITT population,
the clinically evaluable population, and the microbiologically
evaluable population demonstrated that fleroxacin-rifampicin
produced a success rate equivalent to that of standard parenteral
treatment (table 2). The overall cure rate in the ITT population
( ) was 78% and 75% in the fleroxacin-rifampicin andnp 127
standard parenteral therapy groups, respectively. In the pop-
ulation of clinically evaluable patients ( ), the overallnp 119
cure rate was 82% and 80%, respectively, and among the mi-
crobiologically evaluable patients ( ) with complete fol-np 103
low-up data, it was 86% and 84%, respectively. Bacteriological
failure was documented in 15 patients (8 in the fleroxacin-
rifampicin group and 7 in the standard treatment group).
Among these 15 patients, we noted 6 cases of catheter-related
bacteremia (including 1 due to CoNS), 6 osteoarticular infec-
tions, 2 deep-seated abscesses, and 1 case of primary bacteremia.
No development of resistance was noted during fleroxacin-
rifampicin treatment.
Similar proportions of clinical and bacteriologic failures after
S. aureus infections were documented in each group (table 3).
In particular, the proportions of microbiologically documented
failure after catheter-related or primary S. aureus bacteremia
(4 [14%] of 29 patients in the fleroxacin-rifampicin group vs.
2 [13%] of 15 patients in the standard treatment group; Pp
) and osteoarticular infection (2 [11%] of 18 in the flerox-1.0
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Table 1. Demographic and baseline clinical characteristics of 127 patients in the
intention-to-treat population in a study comparing fleroxacin-rifampicin with standard









(n p 59) P
Age, mean years  SD 59.2  17.9 57.1  18.8 .52
Male sex/female sex 44/24 38/21 .97
Weight, mean kg  SD 69  14 73  15 .16
Smoker 12 (18) 9 (15) .81
Transfer from another hospital 5 (7) 4 (7) .86
Prior hospitalization during the 5 years before
randomization 36 (53) 32 (54) .98
Length of hospital stay before randomization,
median days (interquartile range) 7.5 (3.5–13.5) 9 (5–12) .40
Surgery during the 6 months before randomization 8 (12) 10 (17) .45
Infection during the 3 months before randomization 11 (16) 9 (15) .89
Steroid therapy 5 (7) 6 (10) .75
Degree of dependence .61
Able to carry on normal activity 18 (26) 14 (24)
Unable to work, needs assistance 23 (34) 25 (42)
Full dependence on external care 27 (40) 20 (34)
Underlying condition
Cardiovascular disease 26 (38) 21 (36) .85
Diabetes mellitus 16 (24) 10 (17) .39
Cancer 20 (29) 19 (33) .85
Neurological disease 9 (13) 12 (20) .34
Renal disease 7 (10) 5 (8) .77
Rheumatologic disease 7 (10) 4 (7) .54
Respiratory disease 5 (7) 3 (5) .72
Site of primary infectiona
Catheter-related bacteremia 30 (44) 25 (42) .84
Primary bacteremia without identified focus 11 (16) 5 (8) .28
Secondary bacteremia 23 (34) 17 (29) .57
Acute bone and joint infection 18 (26) 17 (29) .84
Chronic osteomyelitis 4 (6) 3 (5) .99
Deep-seated abscess 7 (10) 8 (14) .59
Otherb 2 (3) 2 (3) .99
Microorganism
Staphylococcus aureusc 58 (85) 46 (78) .36
Coagulase-negative staphylococcid 10 (15) 13 (22) .36
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Five patients (4 in the fleroxacin-rifampicin group and 1 in the flucloxacillin group) had 2 sites of
infection.
b Lower respiratory tract infection (in 2 patients) and complicated urinary tract infections (in 2 patients).
c In each study arm, there was 1 case of infection due to methicillin-resistant S. aureus.
d In each study arm, there were 4 cases of infection due to methicillin-resistant coagulase-negative
staphylococci.
acin-rifampicin group vs. 4 [31%] of 13 in the standard treat-
ment group; ) were comparable between groups.Pp .21
Secondary outcome variables. Three patients (4.4%) in
the group receiving fleroxacin-rifampicin and 5 patients (8.5%)
in the standard treatment group died (relative risk, 0.7; 95%
CI, 0.3–1.8; ). The median length of hospital stay afterPp .48
study inclusion was 12 days (interquartile range, 5–32 days) in
the fleroxacin-rifampicin group and 23 days (interquartile
range, 15–42 days) in the standard treatment group (Pp
)..006
Safety and tolerability. We recorded 58 adverse events in
39 patients (23 in the fleroxacin-rifampicin group and 16 in
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Table 2. Assessment of efficacy in patients in the intention-to-treat, clini-
cally evaluable, and microbiologically evaluable populations who were as-
signed to receive fleroxacin-rifampicin or standard parenteral therapy (flu-










Intention-to-treat, cure 53/68 (78) 44/59 (75) 1.1 (0.7–1.6) .66
Clinically evaluable 1.1 (0.7–1.6) .79
Clinical success 53/65 (82) 43/54 (80)
Clinical failure 12/65 (18) 11/54 (20)
Microbiologically evaluable 1.1 (0.6–1.8) .64
Eradication 50/58 (86) 38/45 (84)
Bacteriologic failure 8/58 (14) 7/45 (16)
NOTE. Data are no. of patients who achieved the outcome/no. of patients evaluated (%).
the standard therapy group; ). More adverse events prob-Pp .4
ably related to the study medication were reported from the
group treated with fleroxacin-rifampicin (15 of 68 vs. 5 of 59
patients; ). Seven patients (10%) in that group had mildPp .05
adverse events that were probably related to the study medi-
cation (3 patients had gastrointestinal symptoms, 2 had in-
creased transaminase levels, and 2 were photosensitive), com-
pared with 1 patient (2%) in the standard treatment group,
who had a temporarily decreased leukocyte count.
Eight patients had moderate or severe adverse events in the
group treated with fleroxacin-rifampicin (4 patients had CNS
symptoms with hallucinations and sleeplessness, 3 patients had
hepatitis, and 1 had gastrointestinal symptoms). Six patients
had to discontinue therapy because of toxicity. Four withdraw-
als were attributable to fleroxacin (CNS symptoms), and 2 were
related to rifampicin (hepatitis). In the standard treatment
group, 4 patients (3 with skin rash and 1 with nephritis) had
to stop study medication because of toxicity.
DISCUSSION
This study compared the efficacy and safety of mainly oral
fleroxacin-rifampicin therapy with that of standard parenteral
therapy with flucloxacillin or vancomycin in the treatment of
staphylococcal infection. In the 3 populations analyzed, we con-
sistently observed that the efficacy of fleroxacin-rifampicin was
similar to that of standard parenteral therapy. Moreover, the
rate of cure of invasive S. aureus infections was similar. Al-
though patients who received the fleroxacin-rifampicin regimen
had a shorter length of hospital stay, we observed more adverse
events that were probably related to study medication in this
treatment group.
The few published studies of combination therapy with fluor-
oquinolones and rifampicin have reported mostly favorable
outcomes among patients with right-sided endocarditis or os-
teoarticular infections [3–6, 14]. Senneville et al. [6] studied
17 patients with diabetic foot osteomyelitis treated with oflox-
acin-rifampicin and observed a success rate of 77%, similar to
that observed in our study. Moreover, fluoroquinolone-rifam-
picin combinations have been used successfully for treatment
of other types of infections (e.g., leprosy, brucellosis, and peri-
tonitis due to continuous ambulatory peritoneal dialysis) [15–
17]. Finally, a ciprofloxacin-rifampicin combination was pro-
posed for the prevention of infections in patients with neutro-
penia; however, this regimen did not improve the efficacy of
antibacterial prophylaxis and increased the occurrence of side
effects [18].
The incidence of drug toxicity was higher in the group re-
ceiving fleroxacin-rifampicin. Fleroxacin shares the phototoxic
skin effects observed with other fluoroquinolones that produce
comparable plasma levels, such as enoxacin and pefloxacin [19].
Neurotoxicity was another striking feature of the fleroxacin-
containing regimen, limiting its use for several patients. In pre-
vious experiments, fleroxacin showed dose-dependent adverse
effects on the CNS, leading to insomnia and nightmares [20].
More commonly prescribed, newer fluoroquinolones (e.g.,
moxifloxacin) with excellent antistaphylococcal activity have
lower neurotoxicity and may be valuable alternatives [19, 21].
Fluoroquinolone overuse has become a major concern [22],
because resistance rates to fluoroquinolones have increased in
many countries [23]. Most nosocomial S. aureus strains are
now resistant to fluoroquinolones, thus limiting their usefulness
for clinical practice. However, most community-acquired
MRSA strains are still susceptible to fluoroquinolone-rifam-
picin combinations; thus, these may be considered as alter-
natives to orally available agents such as clindamycin, trimeth-
oprim-sulfamethoxazole, or linezolid [24]. Clearly, local and
individual susceptibility patterns need to be considered before
promoting combination therapies with fluoroquinolones for S.
aureus infections. In Switzerland and other countries with a
low incidence of multidrug-resistant staphylococci, a significant
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Table 3. Cure rates among patients in the clinically (n p 119) and microbiologically
(n p 103) evaluable populations assigned to receive fleroxacin-rifampicin or standard
parenteral therapy (flucloxacillin or vancomycin) for staphylococcal infection, according
to pathogen and infection site.
Population, pathogen










Staphylococcus aureus 44/56 (79) 32/42 (76) 1.1 (0.7–1.6) .81
Catheter-related bacteremia 15/19 (79) 10/11 (91) 0.8 (0.4–1.3) .63
Bone and joint infection 18/22 (82) 11/17 (65) 1.6 (0.7–3.5) .28
Primary bacteremia 10/11 (91) 4/5 (80) 1.4 (0.3–5.9) .54
Othera 1/4 (25) 7/9 (78) 0.2 (0.0–1.5) .22
Coagulase-negative staphylococci
(catheter-related bacteremia) 9/9 (100) 11/12 (92) Undefined 1.0
Microbiologically evaluable
S. aureus 41/49 (84) 27/33 (82) 1.1 (0.6–1.7) 1.0
Catheter-related bacteremia 15/19 (79) 9/10 (90) 0.8 (0.5–1.3) .63
Bone and joint infection 16/18 (89) 9/13 (69) 1.9 (0.6–6.2) .21
Primary bacteremia 10/10 (100) 4/5 (80) Undefined .33
Othera 0/2 5/5 (100) Undefined .05
Coagulase-negative staphylococci
(catheter-related bacteremia) 9/9 (100) 11/12 (92) Undefined 1.0
NOTE. Data are no. of patients who achieved cure/no. of patients evaluated (%). “Undefined” denotes
cells containing a 0 value.
a Patients with deep-seated abscess, lower respiratory tract infection, or complicated urinary tract infection.
proportion of patients with S. aureus infections may still benefit
from this oral combination therapy [25]. In settings with a high
prevalence of fluoroquinolone-resistant staphylococci, other ri-
fampicin-containing combination therapies should be investi-
gated in the future.
Several studies have demonstrated the propensity of S. aureus
to develop resistance to fluoroquinolone monotherapy [26].
We noted the absence of the development of resistance during
fleroxacin-rifampicin treatment. This observation is in agree-
ment with that from an experimental study comparing peflox-
acin alone with pefloxacin-rifampicin for the treatment of os-
teomyelitis due to S. aureus [27]. By contrast, ciprofloxacin
resistance during treatment with ciprofloxacin-rifampicin for
MRSA colonization has been reported [28]. In that study, how-
ever, 5 of the 10 patients with ciprofloxacin-resistant MRSA
isolates had never received ciprofloxacin, indicating possible
exogenous cross-transmission [28].
This study has several important strengths. First, to our
knowledge, this is the largest clinical trial of an oral fluoro-
quinolone-rifampicin combination among patients with staph-
ylococcal infections. Second, we included a heterogeneous pa-
tient population in our trial, representing the spectrum of
staphylococcal infections that clinicians are likely to encounter
in clinical practice. Finally, we performed an extended follow-
up to exclude late bacterial complications. Nevertheless, 2 study
limitations merit consideration. First, fleroxacin is not available
for clinical use in several European countries and the United
States. However, our data about the antistaphylococcal efficacy
of fleroxacin-rifampicin are relevant and should be equally valid
for newer fluoroquinolones, such as moxifloxacin or gatiflox-
acin [29, 30]. Second, the subgroup of patients with catheter-
related bacteremia due to CoNS was too small to provide an
adequate statistical assessment of the efficacy of fleroxacin-ri-
fampicin treatment in this specific type of infection. Therefore,
the overall assessment of efficacy was done on the pooled study
arms.
In summary, this study suggests that an oral regimen
containing fleroxacin-rifampicin may be effective for treating
staphylococcal infections, although tolerance was a limiting fac-
tor for several patients. Patients receiving fleroxacin-rifampicin
had a rapid switch from intravenous to oral dosing and were
discharged earlier than were patients receiving standard par-
enteral treatment. Decisions guiding treatment of staphylococ-
cal infections should consider not only the efficacy but also the
toxicity, the health care costs, and the potential selection of
antibiotic-resistant microorganisms.
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